Invention Grant
- Patent Title: Anti-alpha synuclein antibodies
-
Application No.: US16772043Application Date: 2018-12-13
-
Publication No.: US11292831B2Publication Date: 2022-04-05
- Inventor: Patrick Downey , Kerry Louise Tyson , Marco Kriek , Lorenzo De Lichtervelde , Daniel John Lightwood , David James McMillan , Peter Charles Elliott , Terence Seward Baker
- Applicant: UCB Biopharma SRL
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SRL
- Current Assignee: UCB Biopharma SRL
- Current Assignee Address: BE Brussels
- Agency: Medler Ferro Woodhouse & Mills
- Priority: GB1720970 20171215
- International Application: PCT/EP2018/084689 WO 20181213
- International Announcement: WO2019/115671 WO 20190620
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61P25/16 ; A61K39/00
Abstract:
The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
Public/Granted literature
- US20210101964A1 ANTI-ALPHA SYNUCLEIN ANTIBODIES Public/Granted day:2021-04-08
Information query
